327 related articles for article (PubMed ID: 10545429)
1. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
[TBL] [Abstract][Full Text] [Related]
2. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
Gurbel PA; Serebruany VL; Shustov AR; Bahr RD; Carpo C; Ohman EM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1466-73. PubMed ID: 9626821
[TBL] [Abstract][Full Text] [Related]
3. The platelet-related effects of tenecteplase versus alteplase versus reteplase.
Gurbel PA; Hayes K; Bliden KP; Yoho J; Tantry US
Blood Coagul Fibrinolysis; 2005 Jan; 16(1):1-7. PubMed ID: 15650539
[TBL] [Abstract][Full Text] [Related]
4. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
5. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
8. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
[TBL] [Abstract][Full Text] [Related]
9. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
[TBL] [Abstract][Full Text] [Related]
10. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
Weaver WD
Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
[TBL] [Abstract][Full Text] [Related]
11. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
[TBL] [Abstract][Full Text] [Related]
13. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials in thrombolytic therapy, Part 2: The open-artery hypothesis and RAPID-1 and RAPID-2.
Lopez LM
Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S27-30. PubMed ID: 9397235
[TBL] [Abstract][Full Text] [Related]
15. Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase.
Moser M; Kohler B; Schmittner M; Bode C
BioDrugs; 1998 Jun; 9(6):455-63. PubMed ID: 18020578
[TBL] [Abstract][Full Text] [Related]
16. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
17. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction.
Weaver WD
Eur Heart J; 1996 Sep; 17 Suppl E():14-20. PubMed ID: 11823998
[TBL] [Abstract][Full Text] [Related]
18. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
Noble S; McTavish D
Drugs; 1996 Oct; 52(4):589-605. PubMed ID: 8891469
[TBL] [Abstract][Full Text] [Related]
19. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
[TBL] [Abstract][Full Text] [Related]
20. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
